Sahajanand Medical Technologies Posts Record Q2 FY27 Revenue

Sahajanand Medical Technologies Limited reported record Q2 FY27 revenue of ₹3,734 million, up 24.7% year on year, while EBITDA increased 36.6% to ₹656 million. The company also recorded its highest quarterly profit after tax of ₹265 million, supported by operating leverage and growth across key markets.

How did Sahajanand Medical Technologies perform in Q2 FY27?

Sahajanand Medical Technologies Limited delivered record quarterly revenue, EBITDA and profit after tax for the quarter ended September 30, 2026. Revenue rose 24.7% year on year to ₹3,734 million. EBITDA grew faster than revenue, increasing 36.6% to ₹656 million, while PAT rose 26.6% to ₹265 million.

The result matters because it combines double-digit sales growth with improved profitability. Management attributed the margin improvement to operating leverage, indicating that earnings expanded faster than revenue during the quarter. SMT discussed the results in its Q2 and H1 FY27 earnings call held on November 5, 2026.

What drove SMT's quarterly revenue growth?

SMT's growth was supported by expansion in Europe and a faster pace of growth in India. Europe recorded 23% growth and contributed 36% of quarterly revenue, making it the largest regional contribution specifically disclosed in the available results commentary.

India's growth improved to 15% in Q2 from 6% in Q1. This acceleration is significant in the context of SMT's domestic commercial plans, including the launch of Sironity in India. The source material does not provide absolute revenue figures by geography, product category, or business division.

Management's stated priorities remain centred on execution of product launches and the development of its transcatheter aortic valve implantation, or TAVI, platform. These initiatives form part of the company's operational agenda alongside growth and margin expansion, although the company has not disclosed a financial contribution from either programme in the supplied information.

Which financial figures stood out in the Q2 FY27 results?

The most notable figures were the 24.7% increase in revenue, 36.6% rise in EBITDA and 26.6% growth in PAT. EBITDA growth exceeded revenue growth by 11.9 percentage points, consistent with management's observation that operating leverage supported margin gains.

All absolute figures in the table are stated in ₹ million. The company characterised revenue, EBITDA and PAT as quarterly records. No previous-quarter absolute figures, EBITDA margin, PAT margin, or cash-flow data were provided in the supplied earnings-call summary.

What is SMT's FY27 growth outlook and operating focus?

SMT has maintained constant-currency growth guidance in the mid- to high-teens range for FY27. Constant-currency guidance is designed to assess operating growth without the effect of exchange-rate movements, which is relevant for a company with meaningful revenue from Europe.

The company has also identified margin expansion as a priority. The Q2 result provides evidence of operating leverage in the reported quarter, as EBITDA growth outpaced revenue growth. However, the supplied material does not disclose a target EBITDA margin, a revised annual profit outlook, or a quarterly revenue target.

SMT's stated product agenda includes Sironity in India and continued advancement of its TAVI platform. Product launches can affect the pace and mix of sales, but no launch timetable beyond the stated India focus for Sironity, pricing information, or regulatory milestones for the TAVI platform were included in the available details.

How do the results affect SMT investors and operations?

The Q2 performance gives investors current evidence that SMT is delivering growth in both revenue and earnings while pursuing its FY27 constant-currency guidance. Europe represented 36% of revenue and grew 23%, while India grew 15%, highlighting the relevance of both overseas and domestic execution to the company's results.

For operations, the focus remains on commercialising new products, maintaining momentum in India and Europe, and progressing the TAVI platform. The company made the audio recording of its November 5, 2026 earnings call available on its website after the call. The supplied information does not provide a share-price reaction, analyst estimate comparison, capital-expenditure plan, or revised forecast.

Conclusion

SMT reported a record Q2 FY27, with revenue of ₹3,734 million, EBITDA of ₹656 million and PAT of ₹265 million. Stronger EBITDA growth than revenue points to operating leverage during the quarter, while Europe and India both contributed to the reported sales momentum.

Investors will watch SMT's execution against its mid- to high-teens constant-currency FY27 growth guidance, the rollout of Sironity in India, and progress on the TAVI platform. Further disclosures on product contribution, regional revenue and margin trends will help assess the pace of these priorities.